

## DAFTAR PUSTAKA

1. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nat Rev Immunol.* 2020;20(6):355–62.
2. Wong RSY. Inflammation in COVID-19: from pathogenesis to treatment. *Int J Clin Exp Pathol.* 2021;14(7):831–44.
3. WHO (2020). WHO COVID-19 Dashboard. World Health Organization. <https://covid19.who.int/> - Diakses Februari 2022
4. Satuan Tugas Penanganan COVID-19. Peta Sebaran Kasus Per Provinsi. 2021.
5. DINKOMINFO (2020). Situasi dan Perkembangan COVID-19 Kota Padang. Dinas Komunikasi dan Informatika Kota Padang. <http://corona.padang.go.id/index.php/kondisi-kota-padang> - Diakses Mei 2022
6. Oliveira E, Parikh A, Lopez-Ruiz A, Carrilo M, Goldberg J, Cearras M, *et al.* ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. *PLoS One.* 2021;16:1–14.
7. Tim Kerja Kementerian Dalam Negeri. Pedoman Umum Menghadapi Pandemi Covid-19 Bagi Pemerintah Daerah : Pencegahan, Pengendalian, Diagnosis dan Manajemen. Vol. 53. Jakarta: Kementerian Dalam Negeri; 2020.
8. Kementerian Kesehatan RI. Petunjuk Teknis Pelayanan Puskesmas Pada Masa Pandemi COVID-19 Serial Kedua. Jakarta: KEMENKES RI 2021.
9. WHO Regional Office for Africa. Management of Severe / Critical cases of COVID-19 with non-invasive or mechanical ventilation. 2020.
10. Choudhary S, Sharma K, Silakari O. The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options. *Microb Pathog.* 2020;150:1–18.
11. Sharifpour M, Rangaraju S, Liu M, Alabyad D, Nahab FB, Creel-Bulos CM, *et al.* C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19. *PLoS One.* 2020;15(11):1–10.
12. Carubbi F, Salvati L, Alunno A, Maggi F, Borghi E, Mariani R, *et al.* Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. *Sci Rep.* 2021;11(1):1–11.

13. Ansar W, Ghosh S, editors. *Clinical Significance of C-reactive Protein*. Singapore: Springer Nature; 2020.
14. Boyesen EO, Balsby IM, Henriksen M, Christensen R, Rasmussen JH, Nielsen FE, *et al*. Triage strategies based on c-reactive protein levels and sars-cov-2 tests among individuals referred with suspected covid-19: A prospective cohort study. *J Clin Med*. 2022;11(1):1–10.
15. Jain KK. *The Handbook of Biomarkers*. 2nd ed. New York: Springer Nature; 2017.
16. Kaftan AN, Hussain MK, Algenabi AA, Naser FH, Enaya MA. Predictive value of c-reactive protein, lactate dehydrogenase, ferritin and D-Dimer levels in diagnosing COVID-19 patients: a retrospective study. *Acta Inform Medica*. 2021;29(1):45–50.
17. Yitbarek GY, Walle Ayehu G, Asnakew S, Ayele FY, Bariso Gare M, Mulu AT, *et al*. The role of C-reactive protein in predicting the severity of COVID-19 disease: A systematic review. *SAGE Open Med*. 2021;9:1–8.
18. Deng F, Zhang L, Lyu L, Lu Z, Gao D, Ma X, *et al*. Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19. *Med Clin (Barc)*. 2021;156(7):324–31.
19. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. *J Chinese Med Assoc*. 2020;83(3):217–20.
20. Sugihantono A, Burhan E, Susanto A, Damayanti T, Prasenohadi, Samuedro E, *et al*. *Pedoman Pencegahan Dan Pengendalian Coronavirus Disease (COVID-19)*. 5th ed. Jakarta: Kementerian Kesehatan RI; 2020.
21. Kumar S, Nyodu R, Maurya VK, Saxena SK. Morphology, Genome Organization, Replication, and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). 2020;2:23–31.
22. Cascella M, Rajnik M. Features, Evaluation, and Treatment of Coronavirus (COVID-19). *StatPearls*. 2022.
23. Wong RSY. The SARS-CoV-2 Outbreak: an Epidemiological and Clinical Perspective. *SN Compr Clin Med*. 2020;2(11):1983–91.

24. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA - J Am Med Assoc.* 2020;324(8):782–93.
25. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. *Intervirology.* 2021;64(1):36–47.
26. Gökçe İ, Aydemir K, Ayan S, Altuntaş İ, Erbaş O. Effects of Human Genetic Factors (Ethnicity and Race) on Clinical Severity of SARS-CoV-2 (COVID-19). *J Exp Basic Med Sci.* 2021;1(3):147–58.
27. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. *J Infect Public Health.* 2020;13:1833–9.
28. Jdiaa SS, Mansour R, El Alayli A, Gautam A, Thomas P, Mustafa RA. COVID-19 and chronic kidney disease: an updated overview of reviews. *J Nephrol.* 2022;35(1):69–85.
29. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. *Am J Hypertens.* 2020;33(5):373–4.
30. Muhamad SA, Ugusman A, Kumar J, Skiba D, Hamid AA, Aminuddin A. COVID-19 and Hypertension: The What, the Why, and the How. *Front Physiol.* 2021;12:1–11.
31. Kwok S, Adam S, Ho JH, Iqbal Z, Turkington P, Razvi S, et al. Obesity: A critical risk factor in the COVID -19 pandemic . *Clin Obes.* 2020;10(6):1–11.
32. Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. *AHA.* 2020;142:4–6.
33. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nat Rev Endocrinol.* 2021;17(1):11–30.
34. Lohia P, Sreeram K, Nguyen P, Choudhary A, Khicher S, Yarandi H, et al. Preexisting respiratory diseases and clinical outcomes in COVID-19: a multihospital cohort study on predominantly African American population. *Respir Res.* 2021;22(1):1–9.

35. Yang X, Yu Y, Shu H, Xia J, Liu H, Wu Y, et al. Clinical Course and outcomes of critically ill patients with COVID-19 in Wuhan China. *Lancet Respir Med*. 2020;8(5):475–81.
36. Shaikh FS, Aldhafferi N, Buker A, Alqahtani A, Dey S, Abdulhamid S, et al. Comorbidities and risk factors for severe outcomes in covid-19 patients in Saudi Arabia: A retrospective cohort study. *J Multidiscip Healthc*. 2021;14:2169–83.
37. García-Azorín D, Martínez-Pías E, Trigo J, Hernández-Pérez I, Valle-Peñacoba G, Talavera B, et al. Neurological Comorbidity Is a Predictor of Death in Covid-19 Disease: A Cohort Study on 576 Patients. *Front Neurol*. 2020;11(July):1–8.
38. Safitri M, Suromo LB. Correlation between C-Reactive Protein Level and Blood Urea Nitrogen-Creatinine Ratio in COVID-19 Patients. *Indones J Clin Pathol Med Lab*. 2021;28(1):10–3.
39. Shibata S, Arima H, Asayama K, Hoshida S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. *Hypertens Res*. 2020;43(10):1028–46.
40. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the Cytokine Storm in COVID-19. *J Infect*. 2020;80(6):607–13.
41. Fatoni AZ, Rakhmatullah R. Acute Respiratory Distress Syndrome (ARDS) pada Pneumonia COVID-19. *J Anaesth Pain*. 2021;2(1):11–24.
42. Acar E, Demir A, Yıldırım B, Kaya MG, Gökçek K. The role of hemogram parameters and C-reactive protein in predicting mortality in COVID-19 infection. *Int J Clin Pract*. 2021;75(7):1–11.
43. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708–20.
44. Frija-masson J, Debray M, Boussouar S, Khalil A, Penaud D, Laveneziana P, et al. Residual ground glass opacities three months after Covid-19 pneumonia correlate to alteration of respiratory function: The post Covid M3 study. *Respir Med*. 2021;184.
45. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(20):497–506.



46. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. *Int J Infect Dis.* 2020;95:304–7.
47. Sanyaolu A, Okorie C, Marinkovic A, Patidar R. Comorbidity and its Impact on Patients with COVID-19. *SN Compr Clin Med.* 2020;2:1069–76.
48. Beltrán-García J, Osca-Verdegel R, Pallardó F V., Ferreres J, Rodríguez M, Mulet S, *et al.* Sepsis and Coronavirus disease 2019: Common features and anti-inflammatory therapeutic approaches. *Crit Care Med.* 2020;48(12):1841–4.
49. Luan YY, Yin CH, Yao YM. Update Advances on C-Reactive Protein in COVID-19 and Other Viral Infections. *Front Immunol.* 2021;12(720363).
50. Fazal M. C-Reactive Protein a Promising Biomarker of COVID-19 Severity. *Korean J Clin Lab Sci.* 2021;53(3):201–7.
51. Pagana KD, Pagana TJ. *Manual of Diagnostic and Laboratory Tests.* 6th ed. Canada: Elsevier; 2018.
52. Luan YY, Yao YM. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. *Front Immunol.* 2018;9:1–8.
53. Loio M N, Valls L C. Ferritin: Could be a Health Indicator. *J Fam Med Dis Prev.* 2018;4(2):1–8.
54. Sandnes M, Ulvik RJ, Vorland M, Reikvam H. Hyperferritinemia — A Clinical Overview. 2021;1–25.
55. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. *Int Immunol.* 2017;29(9):401–9.
56. Bou-Abdallah F, Paliakkara JJ, Melman G, Melman A. Reductive mobilization of iron from intact ferritin: Mechanisms and physiological implication. *Pharmaceuticals.* 2018;11(4):2–14.
57. Monica, Wulanjani HA. Correlation between NLR and Ferritin in COVID-19 Patients in ICU Dr . Kariadi Hospital. *Indones J Clin Pathol Med Lab.* 2022;28(2):133–6.
58. Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A, *et al.* The role of C-reactive protein as a prognostic marker in COVID-19. *Int J Epidemiol.* 2021;50(2):420–9.

59. Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. *J Med Virol.* 2020;92(11):2409–11.
60. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, *et al.* Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. *J Med Virol.* 2020;92(7):791–6.
61. Mosquera-Sulbaran JA, Pedrañez A, Carrero Y, Callejas D. C-reactive protein as an effector molecule in Covid-19 pathogenesis. *Rev Med Virol.* 2021;31(6).
62. Ali AM, Rostam HM, Fatah MH, Noori CM, Ali KM, Tawfeeq HM. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. *Immunity, Inflamm Dis.* 2022;10(3):1–10.
63. Alroomi M, Rajan R, Omar AA, Alsaber A, Pan J, Fatemi M, *et al.* Ferritin level: A predictor of severity and mortality in hospitalized COVID-19 patients. *Immunity, Inflamm Dis.* 2021;9(4):1648–55.
64. Habib HM, Ibrahim S, Zaim A, Ibrahim WH. Biomedicine & Pharmacotherapy The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators. *Biomed Pharmacother.* 2021;136:111228.
65. Hulkoti V, Acharya S, Kumar S, Talwar D, Khanna S, Annadatha A, *et al.* Association of serum ferritin with COVID-19 in a cross-sectional study of 200 intensive care unit patients in a rural hospital: Is ferritin the forgotten biomarker of mortality in severe COVID-19. *J Fam Med Prim Care.* 2022;11(5):2045–50.
66. WHO (2021). Adolescent health in the South-East Asia Region. World Health Organization South-East Asia. <https://www.who.int/southeastasia/health-topics/adolescent-health> - Diakses Januari 2023
67. WHO (2022). Ageing and health. World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/ageing-and-health> – Diakses Januari 2023
68. Gesmalah M, Hidajah AC. Epidemiological pattern of covid-19 infection from march tonovember 2020 in situbondo district, east java, Indonesia. *Kesmas.* 2021;16(1):23–8.
69. Rumain B, Schneiderman M, Geliebter A. Prevalence of COVID-19 in adolescents and youth compared with older adults in states experiencing surges. *PLoS One.* 2021;16(3):1–9.

70. Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? *SN Compr Clin Med*. 2020;2(7):874–6.
71. Spiering AE, Vries TJ De. Why Females Do Better : The X Chromosomal TLR7 Gene-Dose Effect in COVID-19. 2021;12:1–13.
72. Gadi N, Wu SC, Spihlman AP, Moulton VR. What's Sex Got to Do With COVID-19? Gender-Based Differences in the Host Immune Response to Coronaviruses. *Front Immunol*. 2020;11:1–22.
73. Clark CE, McDonagh STJ, McManus RJ, Martin U. COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish Hypertension Society. *J Hum Hypertens*. 2021;35(4):304–7.
74. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J Am Med Assoc*. 2020;323(11):1061–9.
75. Ganguli S, Howlader S, Dey K, Barua S, Islam MN, Begum A, et al. Association of food habit with the COVID-19 severity and hospitalization: A cross-sectional study among the recovered individuals in Bangladesh. *Nutr Health*. 2022;16(4).
76. Prasetya IB, Cucunawangsih, Lorens JO, Sungono V, El-Khobar KE, Wijaya RS. Prognostic value of inflammatory markers in patients with COVID-19 in Indonesia. *Clin Epidemiol Glob Heal*. 2021;11:100803.
77. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. *Eur Heart J*. 2021;42(23):2280–3.
78. Zhang Y, Chen Y, Meng Z. Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art. *Front Immunol*. 2020;11(577442):1–12.
79. Rasyid H, Sangkereng A, Harjianti T, Soetjpto AS. Impact of age to ferritin and neutrophil-lymphocyte ratio as biomarkers for intensive care requirement and mortality risk in COVID-19 patients in Makassar, Indonesia. *Physiol Rep*. 2021;9(10):1–10.
80. Mahroum N, Alghory A, Kiyak Z, Alwani A, Seida R, Alrais M, et al. Ferritin – from iron, through inflammation and autoimmunity, to COVID-19. *J Autoimmun*. 2022;126:102778.

81. Herlina. Kematian pada Pasien COVID-19 Berdasarkan Komorbid dan Tingkat Keparahan Death In COVID-19 Patients Based On Comorbid And Severity. 2021;8(1):44–54.
82. Teuben MPJ, Pfeifer R, Teuber H, De Boer LL, Halvachizadeh S, Shehu A, et al. Lessons learned from the mechanisms of posttraumatic inflammation extrapolated to the inflammatory response in COVID-19: A review. *Patient Saf Surg.* 2020;14(1):1–10.
83. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. *Sci Rep.* 2021;11(1):1–9.
84. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. *Mil Med Res.* 2020;7(11):1–12.
85. Melo AKG, Milby KM, Caparroz ALMA, Pinto ACPN, Santos RRP, Rocha AP, et al. Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis. *PLoS One.* 2021;16(6):1–21.
86. Yu H, Wen Q, Lv J, Sun D, Ma Y, Man S, et al. Association between Dietary Patterns Reflecting C-Reactive Protein and Metabolic Syndrome in the Chinese Population. 2022;1–10.
87. Ahmed S, Ansar Ahmed Z, Siddiqui I, Haroon Rashid N, Mansoor M, Jafri L. Evaluation of serum ferritin for prediction of severity and mortality in COVID-19- A cross sectional study. *Ann Med Surg.* 2021;63:1-5.
88. R Mohamed E, Ragab D, Taeimah M, Shaltoot H. Risk factors of intensive care admission and mortality in a cohort of 111 Egyptian COVID-19 patients. *Egypt J Anaesth.* 2022;38(1):514–20.
89. Cheng L, Li H, Li L, Liu C, Yan S, Chen H, et al. Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *J Clin Lab Anal.* 2020;34(10):1–18.
90. Bergamaschi G, Borrelli de Andreis F, Aronico N, Lenti MV, Barteselli C, Merli S, et al. Anemia in patients with Covid-19: pathogenesis and clinical significance. *Clin Exp Med.* 2021;21(2):239–46.